longbridge

ELV: Q3 outperformance lifts 2026 guidance; long-term adjusted EPS growth target remains 12%

Quartr
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Q3 adjusted EPS was $6.99, beating outlook on favorable benefit expense performance and strong execution. 2026 EPS and cash-flow guidance rose, while the long-term adjusted EPS growth target remains at least 12%.Original document: Elevance Health, Inc. [ELV] Slides Release — Oct. 21 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Q3 adjusted EPS was $6.99, beating outlook on favorable benefit expense performance and strong execution. 2026 EPS and cash-flow guidance rose, while the long-term adjusted EPS growth target remains at least 12%.

Original document: Elevance Health, Inc. [ELV] Slides Release — Oct. 21 2026

Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Source: Quartr The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

© 2026 Longbridge｜Terms of ServicePrivacy Policy